Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial ResultsBusiness Wire • 03/30/22
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic CancerBusiness Wire • 02/09/22
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4Business Wire • 01/26/22
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone TargetsBusiness Wire • 01/10/22
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck CancerBusiness Wire • 01/05/22
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022Business Wire • 01/04/22
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor CombinationBusiness Wire • 11/09/21
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare ConferenceBusiness Wire • 11/03/21
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by RadiotherapyBusiness Wire • 10/24/21
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation OncologyBusiness Wire • 10/06/21
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal EffectBusiness Wire • 09/28/21
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021Business Wire • 09/08/21
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/07/21
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung CancerBusiness Wire • 06/30/21
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021Business Wire • 06/07/21
Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck CancerBenzinga • 06/04/21
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 ExposureBusiness Wire • 06/03/21
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global ExpansionBusiness Wire • 06/01/21
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/26/21